A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

BACKGROUND: Only a few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy. Therefore, there is no current consensus on the treatment of these patients. We conducted a randomised phase II study of the modified FOL...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, C, Hwang, J Y, Kim, J-E, Kim, T W, Lee, J S, Park, D H, Lee, S S, Seo, D W, Lee, S K, Kim, M-H, Han, D J, Kim, S C, Lee, J-L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778540/
https://www.ncbi.nlm.nih.gov/pubmed/19826418
http://dx.doi.org/10.1038/sj.bjc.6605374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778540/
https://www.ncbi.nlm.nih.gov/pubmed/19826418
http://dx.doi.org/10.1038/sj.bjc.6605374

Ejemplares similares